PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer

Japanese Journal of Clinical Oncology

Volumn 39, Issue 11, 2009, Pages 727-731

  Shimbo, Masashi ^a   Tomioka, Susumu ^a   Sasaki, Makoto ^a   Shima, Takayuki ^a   Suzuki, Noriyuki ^a   Murakami, Shino ^a   Nakatsu, Hiroomi ^a   Shimazaki, Jun ^b  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Biopsy; Predictive factor; Prostate cancer; PSA doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER STAGING; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

AGED; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 70449403255     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp091     Document Type: Article

References (38)

1. Tabata N, Ohno Y, Matsui R, Sugiyama H, Ito Y, Tsukuma H, et al. Partial cancer prevalence in Japan up to 2020: Estimates based on incidence and survival data from population-based cancer registries. Jpn J Clin Oncol 2008;38:146-57.
2. Stroumbakis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997;49(Suppl 3A):113-8.
3. Roehl KA, Antenor JAV, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9.
4. Steiner MS. High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J Urol 2003;21:15-20.
5. Bishara T, Ramnani DM, Epstein JI. High-grade prostatic intraepithelial neoplasia on needle biopsy. Am J Surg Pathol 2004;28:629-33.
6. Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation. Am J Surg Pathol 2005;29:1201-7.
7. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007;52:1044-51.
8. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
9. Fowler JE, Bigler SA, Miles D, Yalkut D. Predictors of first repeat biology cancer detection with suspected local stage prostate cancer. J Urol 2000;163:813-8.
10. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, et al. Optimal predictors of prostate cancer on repeat prostate biology: A prospective study of 1051 men. J Urol 2000;163:1144-9.
11. Leite KRM, Camara-Lopes LH, Cury J, Dall'Oglio MF, Sanudo A, Srougi M. Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy. Clinics 2008;63:339-42.
12. Connolly D, Black A, Murray LJ, Nambirajan T, Keane PF, Gavin A. The utility of prostate-specific antigen velocity thresholds in clinical practice: A population-based analysis. BJU Int 2008;101:1507-12.
13. Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis 2006;9:169-72.
14. Ramey JR, Halpern EJ, Gomella LG. Ultrasonography and biopsy of the prostate. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology, Vol. 3, 9th edn. Philadelphia: Saunders 2007;2883-95.
15. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: Who, how and when? a review. Eur Urol 2002;42:93-103.
16. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007;70:1131-5.
17. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 2008;54:601-11.
18. Roobol MJ, van der Cruijsen IW, Schroeder FH. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/ml or greater (ERSPC, Rotterdam). Urology 2004;63:892-9.
19. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int 2007;99:775-9.
20. Schroeder FH, Hugosson J, Roobel MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
21. Diavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European Prostate Cancer Detection Study. Prostate 2001;47:111-7.
22. Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, et al. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate 2004;58:277-82.
23. Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. J Urol 2008;180:1325-9.
24. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001;166:1688-91.
25. Havek OR, Noble CB, de la Taille A, Bagiella E, Benson MC. The necessary of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:tOtal ratio) in men with prior negative prostatic biopsies. Curr Opin Urol 1999;9:371-5.
26. Schroeder FH, Carter HB, Wolters T, van den Bergh RCN, Gosselaar C, Bangma CH, et al. Early detection of prostate cancer in 2007 Part 1: PSA and PSA kinetics. Eur Urol 2008;53:468-77.
27. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore longitudinal study of aging. Eur Urol 2008;54:1073-80.
28. Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV. Prostate-specific antigen velocity and the detection of Gleason score 7 to 10 prostate cancer. Cancer 2007;110:1973-8.
29. Wolters T, Roobol MJ, Bangma CH, Schroeder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009;55:385-93.
30. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonon M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003;170:1184-8.
31. Yanke BV, Gonen M, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005;173:421-4.
32. Benecchi L, Pieri AM, Melissari M, Potenzoni M, Pastizzaro CD. A novel nomogram to predict the possibility of prostate cancer on repeat biopsy. J Urol 2008;180:146-9.
33. Ramirez ML, Nelson EC, White RWdeV, Lara PN, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol 2008;54:291-302.
34. Garzeotto M, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 2005;1911-7.
35. Khatami A, Aus G, Damber J-E, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2006;120:170-4.
36. Terai A, Matsui Y, Ichioka K, Ohara H, Terada N, Yoshimura K. Prostate-specific antigen doubling time among Japanese men in an annual health screening program. Int J Urol 2004;11:856-61.
37. Spurgeon SE, Mongoue-Tchokote S, Collins L, Priest R, Hsieh Y-C, Peters LM, et al. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology 2007;69:931-5.
38. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.